271 related articles for article (PubMed ID: 35076701)
21. Generic script share and the price of brand-name drugs: the role of consumer choice.
Rizzo JA; Zeckhauser R
Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
[TBL] [Abstract][Full Text] [Related]
22. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
[TBL] [Abstract][Full Text] [Related]
23. Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013.
Schlenker MB; Trope GE; Buys YM
J Ophthalmol; 2015; 2015():547960. PubMed ID: 25922760
[TBL] [Abstract][Full Text] [Related]
24. Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020.
Liu P; Dhruva SS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jan; 4(1):e2035064. PubMed ID: 33481031
[TBL] [Abstract][Full Text] [Related]
25. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Michaeli DT; Michaeli T
Pharmacoeconomics; 2024 Jan; 42(1):117-131. PubMed ID: 37855850
[TBL] [Abstract][Full Text] [Related]
26. Are drug prices subject to creative destruction? Evidence from the US, 1997-2017.
Lichtenberg FR
Health Econ; 2021 Aug; 30(8):1910-1932. PubMed ID: 33987916
[TBL] [Abstract][Full Text] [Related]
27. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
28. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
29. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
30. Recent trends in systemic psoriasis treatment costs.
Beyer V; Wolverton SE
Arch Dermatol; 2010 Jan; 146(1):46-54. PubMed ID: 20083692
[TBL] [Abstract][Full Text] [Related]
31. Generic Drugs in the United States: Policies to Address Pricing and Competition.
Gupta R; Shah ND; Ross JS
Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Discounted and Undiscounted Cash Prices for Cardiovascular Medications by Type of US Community Pharmacy.
Hong M; Shcherbakova N
J Gen Intern Med; 2021 Jan; 36(1):114-120. PubMed ID: 32885368
[TBL] [Abstract][Full Text] [Related]
33. Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.
Sarpatwari A; Tessema FA; Zakarian M; Najafzadeh MN; Kesselheim AS
Health Aff (Millwood); 2021 May; 40(5):772-778. PubMed ID: 33939506
[TBL] [Abstract][Full Text] [Related]
34. Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study.
Luo J; Kulldorff M; Sarpatwari A; Pawar A; Kesselheim AS
Ann Intern Med; 2019 Nov; 171(9):605-611. PubMed ID: 31569218
[TBL] [Abstract][Full Text] [Related]
35. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
37. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
38. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad.
Mattingly TJ; Seo D; Ostrovsky AM; Vanness DJ; Conti RM
Res Social Adm Pharm; 2021 Aug; 17(8):1489-1495. PubMed ID: 33221266
[TBL] [Abstract][Full Text] [Related]
39. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
40. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
